<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>1699-714X</journal-id>
<journal-title><![CDATA[Revista de la OFIL ]]></journal-title>
<abbrev-journal-title><![CDATA[Rev. OFIL·ILAPHAR]]></abbrev-journal-title>
<issn>1699-714X</issn>
<publisher>
<publisher-name><![CDATA[Organización de Farmacéuticos Ibero-Latinoamericanos]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S1699-714X2021000400010</article-id>
<article-id pub-id-type="doi">10.4321/s1699-714x20210004000010</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Programa de optimización del uso de antimicrobianos (PROA): análisis de indicadores basados en el consumo]]></article-title>
<article-title xml:lang="en"><![CDATA[Antimicrobial stewardship programs: analysis of indicators of antimicrobial agents based on consumption]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Lallana-Sáinz]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Del Diego-Salas]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Bueno-Blázquez]]></surname>
<given-names><![CDATA[AG]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Yagüe-Águeda]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Jiménez-Martínez]]></surname>
<given-names><![CDATA[IM]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Tormo-Domínguez]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Hospital Universitario HLA Moncloa Servicio de Farmacia ]]></institution>
<addr-line><![CDATA[Madrid ]]></addr-line>
<country>España</country>
</aff>
<aff id="Af2">
<institution><![CDATA[,Hospital Universitario HLA Moncloa Servicio de Medicina Preventiva ]]></institution>
<addr-line><![CDATA[Madrid ]]></addr-line>
<country>España</country>
</aff>
<aff id="Af3">
<institution><![CDATA[,Hospital Universitario HLA Moncloa Servicio de Medicina Intensiva ]]></institution>
<addr-line><![CDATA[Madrid ]]></addr-line>
<country>España</country>
</aff>
<aff id="Af4">
<institution><![CDATA[,Hospital Universitario HLA Moncloa Servicio de Medicina Interna ]]></institution>
<addr-line><![CDATA[Madrid ]]></addr-line>
<country>España</country>
</aff>
<aff id="Af5">
<institution><![CDATA[,Hospital Universitario HLA Moncloa Dirección de Planificación y Desarrollo ASISA ]]></institution>
<addr-line><![CDATA[Madrid ]]></addr-line>
<country>España</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>12</month>
<year>2021</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>12</month>
<year>2021</year>
</pub-date>
<volume>31</volume>
<numero>4</numero>
<fpage>386</fpage>
<lpage>391</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://scielo.isciii.es/scielo.php?script=sci_arttext&amp;pid=S1699-714X2021000400010&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.isciii.es/scielo.php?script=sci_abstract&amp;pid=S1699-714X2021000400010&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.isciii.es/scielo.php?script=sci_pdf&amp;pid=S1699-714X2021000400010&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[RESUMEN  Objetivos: Implantar un programa de optimización del uso de antimicrobianos (PROA) para intervenir en el uso de antimicrobianos. Analizar el impacto de las intervenciones mediante indicadores basados en el consumo.  Métodos: Fase 1. Creación equipo PROA: nombramiento; asesoramiento externo; formación; desarrollo programa informático. Fase 2. Análisis indicadores de consumo: estudio retrospectivo de intervención cuasi-experimental con evaluación pre-post: se evaluaron los indicadores del uso de antimicrobianos basados en el consumo en fase no-intervención y en fase intervención. El programa PROA consistió en un modelo de intervención no restrictivo.  Resultados: Se formó e implantó el equipo PROA como órgano estructural y organizativo para la consulta, intervención y vigilancia del uso de antimicrobianos. Durante la fase intervención se realizaron 134 recomendaciones: terapia secuencial (12,69%), cambio de antimicrobiano/desescalada terapéutica (31,34%), suspensión de tratamiento antimicrobiano (55,97%); el grado de aceptación fue del 67,16%. Se analizaron 13 indicadores. En 11 de ellos se observó mejoría: consumo global antibacterianos (-2,26%), consumo global antifúngicos sistémicos (-40,60%), consumo carbapenémicos (-22,63%), consumo fluoroquinolonas (-16,52%), ratiomacrólidos i.v./fluoroquinolonas respiratorias i.v. (17,49%), ratiometronidazol/carbapenémicos + piperacilinatazobactam (15,82%), consumo fosfomicina (69,21%), ratioagentes anti-SASM/agentes anti-SARM (45,14%), ratio amoxicilina-clavulánico/piperacilina-tazobactam (24,38%), diversificación betalactámicos antipseudomónicos (7,61%), ratio fluconazol/equinocandinas (8,74%). Los indicadores en los que se obtuvo resultado negativo fueron: terapia secuencial (-8,89%), ratioamoxicilina/amoxicilina-clavulánico (-4,03%).  Conclusiones: Los resultados obtenidos muestran la efectividad del programa PROA mediante la evaluación de indicadores basados en el consumo y permiten medir el impacto de las intervenciones realizadas, identificar estrategias más efectivas y priorizar las intervenciones a realizar en el futuro.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[SUMMARY  Objectives: Implementation of a program for optimizing the use of antibiotics (PROA) to manage the use of antimicrobials. Analyse the impact through indicators based on consumption.  Methods: Phase 1. Creation of PROA: appointment; external advice; training; software development. Phase 2. Consumption indicators analysis: interventional, quasi-experimental, retrospective study with pre-post evaluation: indicators based on consumption were evaluated in non-intervention phase and in intervention phase. PROA consisted of a non-restrictive intervention model.  Results: PROA was formed and implemented as a structural and managing body for the advice, intervention and monitoring of the use of antimicrobials. During the intervention phase, 134 recommendations related to sequential therapy IV/PO (12.69%), change of antimicrobial/de-escalation (31.34%), discontinuation of antimicrobial treatment (55.97%) were made; the degree of acceptance was 67.16%. 13 indicators based on consumption were analysed. 11 of them led to an improvement: antibacterials global consumption (-2.26%), systemic antifungals global consumption (-40.60%), carbapenems consumption (-22.63%), fluoroquinolones consumption (-16.52%), macrolide IV/fosfomycin consumption (69.21%), antiMSSA agents/anti-MRSA agents ratio (45.14%), amoxicillin-clavulanic/piperacillin-tazobactam ratio (24.38%), diversification antipseudomonic beta-lactam (7.61%), fluconazole/echinocandins ratio (8.74%). Indicators with negative result were: sequential therapy IV/PO (-8.89%), amoxicillin/amoxicillin-clavulanic ratio (-4.03%).  Conclusions: The results obtained show the effectiveness of PROA at our hospital when evaluating indicators based on consumption and allowing to measure the impact of the interventions made, identify the most effective strategies and prioritize the interventions to be carried out in the future.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[Antiinfecciosos]]></kwd>
<kwd lng="es"><![CDATA[uso terapéutico]]></kwd>
<kwd lng="es"><![CDATA[indicadores de calidad de la atención de la salud]]></kwd>
<kwd lng="es"><![CDATA[programas de optimización del uso de antimicrobianos]]></kwd>
<kwd lng="es"><![CDATA[utilización de medicamentos]]></kwd>
<kwd lng="es"><![CDATA[política antibiótica]]></kwd>
<kwd lng="en"><![CDATA[Anti-infective agents]]></kwd>
<kwd lng="en"><![CDATA[quality indicators]]></kwd>
<kwd lng="en"><![CDATA[health care]]></kwd>
<kwd lng="en"><![CDATA[antimicrobial stewardship]]></kwd>
<kwd lng="en"><![CDATA[drug utilization review]]></kwd>
<kwd lng="en"><![CDATA[drug resistance]]></kwd>
<kwd lng="en"><![CDATA[microbial]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rodríguez-Baño]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Paño-Pardo]]></surname>
<given-names><![CDATA[JR]]></given-names>
</name>
<name>
<surname><![CDATA[Álvarez-Rocha]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Asensio]]></surname>
<given-names><![CDATA[Á]]></given-names>
</name>
<name>
<surname><![CDATA[Calbo]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Cercenado]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Programs for optimizing the use of antibiotics (PROA) in Spanish hospitals: GEIH-SEIMC, SEFH and SEMPSPH consensus document]]></article-title>
<source><![CDATA[Farm Hosp]]></source>
<year>2012</year>
<volume>36</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>33.e1-33.e10</page-range></nlm-citation>
</ref>
<ref id="B2">
<label>2.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Baur]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Gladstone]]></surname>
<given-names><![CDATA[BP]]></given-names>
</name>
<name>
<surname><![CDATA[Burkert]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Carrara]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Foschi]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Döbele]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Effect of antibiotic stewardship on the incidence of infection and colonisation with antibiotic resistant bacteria and Clostridium difficile infection: a systematic review and metaanalysis]]></article-title>
<source><![CDATA[Lancet Infect Dis]]></source>
<year>2017</year>
<volume>17</volume>
<page-range>990-1001</page-range></nlm-citation>
</ref>
<ref id="B3">
<label>3.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ugalde-Espiñeira]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Programa de optimización del uso de antimicrobianos (PROA). Experiencia en un hospital secundario]]></article-title>
<source><![CDATA[Rev Esp Quimioter]]></source>
<year>2016</year>
<volume>29</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>183-9</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>4.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Barlam]]></surname>
<given-names><![CDATA[TF]]></given-names>
</name>
<name>
<surname><![CDATA[Cosgrove]]></surname>
<given-names><![CDATA[SE]]></given-names>
</name>
<name>
<surname><![CDATA[Abbo]]></surname>
<given-names><![CDATA[LM]]></given-names>
</name>
<name>
<surname><![CDATA[MacDougall]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Schuetz]]></surname>
<given-names><![CDATA[AN]]></given-names>
</name>
<name>
<surname><![CDATA[Septimus]]></surname>
<given-names><![CDATA[EJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Implementing an Antibiotic Stewardship Program: Guidelines by the Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America]]></article-title>
<source><![CDATA[Clin Infect Dis]]></source>
<year>2016</year>
<volume>62</volume>
<numero>10</numero>
<issue>10</issue>
<page-range>e51-77</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gutiérrez-Urbón]]></surname>
<given-names><![CDATA[JM]]></given-names>
</name>
<name>
<surname><![CDATA[Gil-Navarro]]></surname>
<given-names><![CDATA[MV]]></given-names>
</name>
<name>
<surname><![CDATA[Moreno-Ramos]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Núñez-Núñez]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Paño-Pardo]]></surname>
<given-names><![CDATA[JR]]></given-names>
</name>
<name>
<surname><![CDATA[Periáñez-Párraga]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Indicadores del uso hospitalario de antimicrobianos basados en el consumo]]></article-title>
<source><![CDATA[Farm Hosp]]></source>
<year>2019</year>
<volume>43</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>94-100</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6.</label><nlm-citation citation-type="">
<collab>WHO Collaborating Centre for Drug Statistics Methodology</collab>
<source><![CDATA[Guidelines for ATC classification and DDD assignment 2018]]></source>
<year>2018</year>
</nlm-citation>
</ref>
<ref id="B7">
<label>7.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Retamar]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Rodríguez-Baño]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Un paso adelante en la definición de indicadores PROA: Medir bien para trabajar mejor]]></article-title>
<source><![CDATA[Farm Hosp]]></source>
<year>2019</year>
<volume>43</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>77-8</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Teshome]]></surname>
<given-names><![CDATA[BF]]></given-names>
</name>
<name>
<surname><![CDATA[Vouri]]></surname>
<given-names><![CDATA[SM]]></given-names>
</name>
<name>
<surname><![CDATA[Hampton]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Kollef]]></surname>
<given-names><![CDATA[MH]]></given-names>
</name>
<name>
<surname><![CDATA[Micek]]></surname>
<given-names><![CDATA[ST]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Duration of exposure to antipseudomonal ß-lactam antibiotics in the critically ill and development of new resistance]]></article-title>
<source><![CDATA[Pharmacotherapy]]></source>
<year>2019</year>
<volume>39</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>261-70</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Retamar]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Martín]]></surname>
<given-names><![CDATA[ML]]></given-names>
</name>
<name>
<surname><![CDATA[Molina]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[del Arco]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Evaluating the quality of antimicrobial prescribing: is standardisation possible?]]></article-title>
<source><![CDATA[Enferm Infecc Microbiol Clin]]></source>
<year>2013</year>
<volume>31</volume>
<numero>Suppl 4</numero>
<issue>Suppl 4</issue>
<page-range>25-30</page-range></nlm-citation>
</ref>
<ref id="B10">
<label>10.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[DePestel]]></surname>
<given-names><![CDATA[DD]]></given-names>
</name>
<name>
<surname><![CDATA[Eiland]]></surname>
<given-names><![CDATA[EH]]></given-names>
</name>
<name>
<surname><![CDATA[Lusardi]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Destache]]></surname>
<given-names><![CDATA[CJ]]></given-names>
</name>
<name>
<surname><![CDATA[Mercier]]></surname>
<given-names><![CDATA[RC]]></given-names>
</name>
<name>
<surname><![CDATA[McDaneld]]></surname>
<given-names><![CDATA[PM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Assessing appropriateness of antimicrobial therapy: in the eye of the interpreter]]></article-title>
<source><![CDATA[Clin Infect Dis]]></source>
<year>2014</year>
<volume>59</volume>
<numero>Suppl 3</numero>
<issue>Suppl 3</issue>
<page-range>S154-61</page-range></nlm-citation>
</ref>
<ref id="B11">
<label>11.</label><nlm-citation citation-type="">
<collab>Grupo de trabajo de Atención Farmacéutica en Enfermedades Infecciosas de la Sociedad Española de Farmacia Hospitalaria</collab>
<source><![CDATA[Aplicación consumo antiinfecciosos (DDD)]]></source>
<year></year>
</nlm-citation>
</ref>
<ref id="B12">
<label>12.</label><nlm-citation citation-type="book">
<source><![CDATA[Indicadores de uso de antibióticos sector comunitario. Plan Nacional de Resistencia a antibióticos]]></source>
<year>2018</year>
<publisher-loc><![CDATA[Madrid ]]></publisher-loc>
<publisher-name><![CDATA[Agencia Española de Medicamentos y Productos Sanitarios]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B13">
<label>13.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Coenen]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Ferech]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Haaijer-Ruskamp]]></surname>
<given-names><![CDATA[FM]]></given-names>
</name>
<name>
<surname><![CDATA[Butler]]></surname>
<given-names><![CDATA[CC]]></given-names>
</name>
<name>
<surname><![CDATA[Vander Stichele]]></surname>
<given-names><![CDATA[RH]]></given-names>
</name>
<name>
<surname><![CDATA[Verheij]]></surname>
<given-names><![CDATA[TJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[European Surveillance of Antimicrobial Consumption (ESAC): quality indicators for outpatient antibiotic use in Europe]]></article-title>
<source><![CDATA[Qual Saf Health Care]]></source>
<year>2007</year>
<volume>16</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>440-5</page-range></nlm-citation>
</ref>
<ref id="B14">
<label>14.</label><nlm-citation citation-type="book">
<source><![CDATA[Indicadores de uso de antibióticos en hospitales. Plan Nacional de Resistencia a antibióticos]]></source>
<year>2018</year>
<publisher-loc><![CDATA[Madrid ]]></publisher-loc>
<publisher-name><![CDATA[Agencia Española de Medicamentos y Productos Sanitarios]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B15">
<label>15.</label><nlm-citation citation-type="">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Aguado]]></surname>
<given-names><![CDATA[JM]]></given-names>
</name>
<name>
<surname><![CDATA[Fortún]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<source><![CDATA[Guía de recomendaciones en la Terapia Secuencial Antibiótica (TSA). Guías clínicas SEIMC]]></source>
<year>2006</year>
</nlm-citation>
</ref>
<ref id="B16">
<label>16.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sevinç]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Prins]]></surname>
<given-names><![CDATA[JM]]></given-names>
</name>
<name>
<surname><![CDATA[Koopmans]]></surname>
<given-names><![CDATA[RP]]></given-names>
</name>
<name>
<surname><![CDATA[Langendijk]]></surname>
<given-names><![CDATA[PN]]></given-names>
</name>
<name>
<surname><![CDATA[Bossuyt]]></surname>
<given-names><![CDATA[PM]]></given-names>
</name>
<name>
<surname><![CDATA[Dankert]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Early switch from intravenous to oral antibiotics: guidelines and implementation in a large teaching hospital]]></article-title>
<source><![CDATA[J Antimicrob Chemother]]></source>
<year>1999</year>
<volume>43</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>601-6</page-range></nlm-citation>
</ref>
<ref id="B17">
<label>17.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Davey]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Marwick]]></surname>
<given-names><![CDATA[CA]]></given-names>
</name>
<name>
<surname><![CDATA[Scott]]></surname>
<given-names><![CDATA[CL]]></given-names>
</name>
<name>
<surname><![CDATA[Charani]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[McNeil]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Brown]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Interventions to improve antibiotic prescribing practices for hospital inpatients]]></article-title>
<source><![CDATA[Cochrane Database Syst Rev]]></source>
<year>2017</year>
<numero>2</numero>
<issue>2</issue>
</nlm-citation>
</ref>
<ref id="B18">
<label>18.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ramsay]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Brown]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Hartman]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Davey]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Room for improvement: a systematic review of the quality of evaluations of interventions to improve hospital antibiotic prescribing]]></article-title>
<source><![CDATA[J Antimicrob Chemother]]></source>
<year>2003</year>
<volume>52</volume>
<page-range>764-71</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
